Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

医学 2型糖尿病 内科学 胰岛素 胰高血糖素样肽1受体 糖尿病 低血糖 内分泌学 减肥 兴奋剂 基础(医学) 体重增加 荟萃分析 肥胖 受体 体重
作者
Conrad Eng,Caroline K. Kramer,Bernard Zinman,Ravi Retnakaran
出处
期刊:The Lancet [Elsevier BV]
卷期号:384 (9961): 2228-2234 被引量:367
标识
DOI:10.1016/s0140-6736(14)61335-0
摘要

Combination treatment with a glucagon-like peptide-1 (GLP-1) agonist and basal insulin has been proposed as a treatment strategy for type 2 diabetes that could provide robust glucose-lowering capability with low risk of hypoglycaemia or weight gain. We thus did a systematic review and meta-analysis of randomised controlled trials to assess the effect of this combination treatment on glycaemic control, hypoglycaemia, and weight gain in patients with type 2 diabetes.We systematically searched PubMed, Embase, Cochrane, Web of Knowledge, FDA.gov, and ClinicalTrials.gov for randomised controlled trials (published between Jan 1, 1950, and July 29, 2014; no language restrictions) comparing GLP-1 agonist and basal insulin combination treatment to other anti-diabetic treatments. Our main endpoints were glycaemic control, hypoglycaemia, and change in weight. We assessed pooled data by use of a random-effects model.Of 2905 identified studies, 15 were eligible and were included in our analysis (N=4348 participants). Compared with other anti-diabetic treatments, GLP-1 agonist and basal insulin combination treatment yielded an improved mean reduction in glycated haemoglobin (HbA1c) of -0·44% (95% CI -0·60 to -0·29), an improved likelihood of achieving the target HbA1c of 7·0% or lower (relative risk [RR] 1·92; 95% CI 1·43 to 2·56), no increased relative risk of hypoglycaemia (0·99; 0·76 to 1·29), and a mean reduction in weight of -3·22 kg (-4·90 to -1·54). Furthermore, compared with basal-bolus insulin regimens, the combination treatment yielded a mean reduction in HbA1c of -0·1% (-0·17 to -0·02), with lower relative risk of hypoglycaemia (0·67, 0·56 to 0·80), and reduction in mean weight (-5·66 kg; -9·8 to -1·51).GLP-1 agonist and basal insulin combination treatment can enable achievement of the ideal trifecta in diabetic treatment: robust glycaemic control with no increased hypoglycaemia or weight gain. This combination is thus a potential therapeutic strategy that could improve the management of patients with type 2 diabetes.None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
CC关注了科研通微信公众号
2秒前
msp发布了新的文献求助10
3秒前
LY完成签到,获得积分10
3秒前
4秒前
宋笨笨完成签到 ,获得积分10
5秒前
5秒前
1x3发布了新的文献求助10
6秒前
Sam完成签到,获得积分10
9秒前
于雷是我完成签到,获得积分10
10秒前
yqz发布了新的文献求助30
11秒前
13秒前
香蕉觅云应助粉条采纳,获得10
15秒前
英姑应助Nicole采纳,获得10
16秒前
朴实子骞完成签到 ,获得积分10
17秒前
chenxin完成签到,获得积分10
18秒前
Iiiilr完成签到 ,获得积分10
18秒前
生动刺猬发布了新的文献求助10
18秒前
852应助小萝卜采纳,获得10
19秒前
夕阳与茶完成签到,获得积分10
19秒前
佳佳应助CyS采纳,获得10
19秒前
20秒前
乱武完成签到,获得积分10
20秒前
Aloha完成签到,获得积分10
21秒前
22秒前
11应助夕阳与茶采纳,获得10
23秒前
HJJHJH发布了新的文献求助50
24秒前
25秒前
eeeating完成签到,获得积分10
26秒前
田様应助notsoeasy采纳,获得10
27秒前
刘旋发布了新的文献求助10
27秒前
和谐绍辉完成签到,获得积分20
27秒前
科研通AI2S应助CyS采纳,获得10
27秒前
CC发布了新的文献求助10
27秒前
28秒前
张雷应助1x3采纳,获得20
28秒前
30秒前
帅气访天完成签到,获得积分10
30秒前
小萝卜发布了新的文献求助10
32秒前
粉条发布了新的文献求助10
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976210
求助须知:如何正确求助?哪些是违规求助? 3520366
关于积分的说明 11203088
捐赠科研通 3256965
什么是DOI,文献DOI怎么找? 1798570
邀请新用户注册赠送积分活动 877738
科研通“疑难数据库(出版商)”最低求助积分说明 806516